Global PCOS Drugs Market 2014-2018

Global PCOS Drugs Market 2014-2018

Category : Pharmaceuticals
Published On : April  2014
Pages : 88



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About PCOS Drugs
PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS.
TechNavio's analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.65 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS. 
TechNavio's report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
• APAC
Key Vendors
• Bristol Myers Squibb Co.
• Merck & Co. Inc. 
• Novartis AG 
• Sanofi SA 
• Teva Pharmaceutical Inc.
Other Prominent Vendors
 
• AstraZeneca plc 
• Catalysis SL 
• Crinetics Pharmaceuticals Inc.
• Dexa Medica Group 
• EffRx Inc.
• Neurocrine Biosciences Inc.
Market Driver
• Increase in Patient Population.
• For a full, detailed list, view our report.
Market Challenge
• Lack of Approved Drugs.
• For a full, detailed list, view our report.
Market Trend
• Increase in Awareness of PCOS Drugs.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Competitive Analysis of Marketed Products

08. Pipeline Snapshot

09. Rate of Incidence and Prevalence


09.1.1 Americas

09.1.2 Europe

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape


18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Vendors Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Sanofi SA

19.1.1 Key Facts

19.1.2 Business Description

19.1.3 Business Segmentation

19.1.4 Revenue by Business Segmentation

19.1.5 Revenue Comparison 2012 and 2013

19.1.6 Sales by Geography

19.1.7 Business Strategy

19.1.8 Key Developments

19.1.9 SWOT Analysis

19.1.10 Strengths

19.1.11 Weakness

19.1.12 Opportunities

19.1.13 Threats

19.2 Bristol Myers Squibb Co.

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Key Product Offerings

19.2.4 Sales by Geography

19.2.5 Business Strategy

19.2.6 Key Information

19.2.7 SWOT Analysis

19.2.8 Strengths

19.2.9 Weaknesses

19.2.10 Opportunities

19.2.11 Threats

19.3 Novartis A.G.

19.3.1 Key Facts

19.3.2 Business Description

19.3.3 Business Segmentation

19.3.4 Revenue by Business Segmentation

19.3.5 Revenue Comparison 2012 and 2013

19.3.6 Sales by Geography

19.3.7 Business Strategy

19.3.8 Key Developments

19.4 SWOT Analysis

19.4.1 Strengths

19.4.2 Weaknesses

19.4.3 Opportunities

19.4.4 Threats

19.5 Teva Pharmaceutical Inc.

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Revenue by Business Segmentation

19.5.5 Revenue Comparison  2012 and 2013

19.5.6 Revenue Segmentation by Geography

19.5.7 Business Strategy

19.5.8 Key Developments

19.5.9 SWOT Analysis

19.5.10 Strengths

19.5.11 Weakness

19.5.12 Opportunities

19.5.13 Threats

19.6 Merck & Co. Inc.

19.6.1 Key Facts

19.6.2 Business Description

19.6.3 Business Segmentation

19.6.4 Revenue by Business Segmentation

19.6.5 Revenue Comparison 2012 and 2013

19.6.6 Sales by Geography

19.6.7 Business Strategy

19.6.8 Key Developments

19.6.9 SWOT Analysis

19.6.10 Strengths

19.6.11 Weaknesses

19.6.12 Opportunities

19.6.13 Threats

20. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global PCOS Drugs Market 2013-2018 (US$ million)

Exhibit 3: Global PCOS Drugs Market by Geographical Segmentation 2013

Exhibit 4: Sanofi SA: Business Segmentation

Exhibit 5: Sanofi SA: Revenue by Business Segmentation 2013

Exhibit 6: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 7: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

Exhibit 8: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)

Exhibit 9: Bristol-Myers Squibb Co.: Sales by Geographical Segmentation  2013

Exhibit 10: Novartis AG: Business Segmentation

Exhibit 11: Novartis AG: Revenue by Business Segmentation 2013

Exhibit 12: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 13: Novartis AG: Revenue by Geographical Segmentation 2013

Exhibit 14: Teva Pharmaceutical Industries Ltd.: Business Segmentation

Exhibit 15: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013

Exhibit 16: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 17: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013

Exhibit 18: Merck & Co. Inc.: Business Segmentation 2013

Exhibit 19: Merck & Co. Inc.: Revenue by Business Segmentation 2013

Exhibit 20: Merck & Co. Inc.: Revenue by Business Segmentation 2012 and 2013 (US$ billion)

Exhibit 21: Merck & Co. Inc.: Revenue by Geographical Segmentation 2013



Enquiry Before Buy